Bellevue Asset Management’s Jazz Pharmaceuticals JAZZ Stock Holding History

Bellevue Asset Management’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-11	Closed	-$1.87K	–	435
2025 Q4	$1.87K	Buy	+11	New	+$1.69K	﹤0.01%	446
2021 Q4	–	Sell	-158	Closed	-$21K	–	580
2021 Q3	$21K	Hold	158	–	–	0.01%	280
2021 Q2	$28K	Hold	158	–	–	0.02%	246
2021 Q1	$26K	Hold	158	–	–	0.02%	257
2020 Q4	$27K	Hold	158	–	–	0.02%	243
2020 Q3	$23K	Sell	158 -42	-21%	-$5.21K	0.02%	247
2020 Q2	$22K	Hold	200	–	–	0.02%	256
2020 Q1	$22K	Buy	+200	New	+$25.9K	0.02%	253

Other funds holding JAZZ

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Bellevue Asset Management's JAZZ Position: Q1 2026 in Review

Bellevue Asset Management sold out of Jazz Pharmaceuticals (JAZZ) in Q1 2026, closing a stake of 11 shares — an estimated $1.87K sold.

Bellevue Asset Management first reported a position in JAZZ in Q1 2020 and held it in 8 quarters. The position peaked at $28K in Q2 2021. 570 funds tracked by Wall St. Rank hold JAZZ as of Q1 2026.

Bellevue Asset Management reported no remaining Jazz Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
Bellevue Asset Management sold 11 Jazz Pharmaceuticals shares in Q1 2026, an estimated $1.87K.
Bellevue Asset Management first reported a position in Jazz Pharmaceuticals in Q1 2020 and held it in 8 quarters.
Bellevue Asset Management's Jazz Pharmaceuticals position peaked at $28K in Q2 2021.
570 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q1 2026.

Based on Bellevue Asset Management's 13F filing for Q1 2026, filed 24 Apr 2026.